NCT00089063View on ClinicalTrials.gov

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Ciliary Body and Choroid Melanoma, Medium/Large SizeExtraocular Extension MelanomaIris MelanomaStage IIB MelanomaStage IIC MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma
Interventions
BIOLOGICAL

tyrosinase peptide

Given SC

BIOLOGICAL

gp100 antigen

Given SC

BIOLOGICAL

MART-1 antigen

Given SC

BIOLOGICAL

incomplete Freund's adjuvant

Given SC

DRUG

Montanide ISA 51 VG

Given SC

BIOLOGICAL

sargramostim

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

90033-0804

University of Southern California, Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00089063 - Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma | Biotech Hunter | Biotech Hunter